Advancing cancer
diagnosis and prognosis.
Envision Sciences is a biomarker development company.
Our primary focus is on cancer diagnostics and prognostics. Our goal is to lead the way in providing high specificity and sensitivity outcomes across various cancer indications.
See how our groundbreaking work
is improving results for patients.
A revolution in prostate cancer biomarkers.
Our biomarker solutions provide clinicians with more detailed information about the level and activity of a cancer, allowing a more accurate diagnosis and improved treatment decisions for their patients across a complete diagnostic and prognostic spectra.
Our leading edgeCutting edge R&D
Pioneering breakthroughs in detection, understanding and prediction of cancer outcomes.
More accurate diagnosis
Clearer advice on the grading and status of cancer in clinical pathology samples.
Improved treatment
More detailed information on the level and activity of a cancer to assist patient care decisions.
Patient-centric
Pioneering the future of diagnostics through patient-centric informed decision-making.
From discovery to commercialisation.
Founded on innovative cancer biomarker technologies, our comprehensive clinical program strives to continually improve cancer diagnostic and prognostic applications, including the development of tissues and blood tests for prostate, colorectal and ovarian cancer and melanoma.
About us
Latest News
Quest Diagnostics Launches Novel Prostate Cancer Test Aimed at Improving Diagnosis and Grading.
July 13 2023
Leading US provider of diagnostic services utilises Envision Science’s proprietary biomarkers and technology with a goal of improving diagnosis and grading of prostate cancer.
Read press releaseContact us
Contact us with any inquiries or assistance you may require; we are always available to help.
